Newsroom | 10372 results

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026. Mr. Smith will continue to lead Alto’s finance function and oversee corporate strategy and business development, reporting to Amit Etkin, M.D., Ph.D., Alto’s founder, chief executive officer and c...

SAN FRANCISCO--(BUSINESS WIRE)--For more than two decades, researchers have identified hundreds of genes that increase the risk of autism spectrum disorder (ASD). Yet multiple fundamental questions have remained unanswered: among them, how do mutations in these genes lead directly to changes in brain development and how can that knowledge be translated into more effective therapies? In a landmark study published today in Science, scientists at the Quantitative Biosciences Institute (QBI) and th...

MIAMI & LEAWOOD, Kan.--(BUSINESS WIRE)--The American Medical Society for Sports Medicine (AMSSM) and OpenEvidence today announced a partnership that will focus on co-developing AI-powered educational resources on sports medicine for both patients and clinicians. This exclusive collaboration brings the expertise of AMSSM’s sports medicine physicians to OpenEvidence, the leading AI-powered clinical decision support platform, and will build on the AMSSM’s robust foundation of educational materials....

PRINCE FREDERICK, Md.--(BUSINESS WIRE)--Greenspace Health will host an educational webinar bringing together behavioral health leaders from across the sector to explore the growing financial and strategic value of Measurement-Based Care (MBC). The session will examine how organizations are leveraging outcome data to strengthen grant applications, succeed in value-based care arrangements, and reduce costly challenges like client no-shows and early dropout from care.WHAT:Beyond Outcomes: The ROI o...

REMOTE-FIRST COMPANY/TAMPA, Fla.--(BUSINESS WIRE)--NextGen Healthcare’s Behavioral Health Suite has been named the No. 1 platform for independent behavioral health practices in the Black Book Market Research Q3 2026 Behavioral Health EHR and Practice Management Platform Rankings for Independent Ambulatory Practices. This ranking is based on feedback from over 660 verified users representing 101 independent behavioral health organizations. The study examined physician-led and multidisciplinary p...

SEATTLE--(BUSINESS WIRE)--FINAO SPV Inc., is working with the YMCA to build The YMCA Wellness Café™, a HIPAA compliant wellness chain that will serve the global YMCA network....

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events: Stifel Hosted Webinar: Definium Therapeutics Virtual Fireside Chat Presentation Date and Time: T...

ENCINITAS, Calif.--(BUSINESS WIRE)--Gen Z is spending more on wellness, and feeling worse for it. That's the top-line finding of the inaugural Body Clock Report, released today by Owaves, the circadian-health company behind BodyClock AI™. The survey of 1,000 U.S. college students finds that Gen Z spends an average of $1,070 per year on wellness products and health-tracking tools, yet many report frequent anxiety, loneliness, and emotional exhaustion.The tracking-action divideA closer look at the...

RUTHERFORD, Calif.--(BUSINESS WIRE)--Today, One Mind™ is proud to announce the recipients of the 2026 One Mind Rising Star Awards, a program that fuels breakthrough research to deepen understanding of the brain and mental health conditions, enhance detection and diagnosis, and drive the treatment and prevention of psychiatric disorders. This year, five visionary scientists conducting research at Children’s Hospital of Philadelphia, Columbia University, Harvard University, Massachusetts Eye and...

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today reported new nonclinical data on the antidepressant mechanism of action for elunetirom, its lead investigational therapy in Phase 2 development for adjunctive treatment of bipolar depression and major depressive disorder (MDD). The data show that elunetirom rapidly increased the number of synaptic connections between neurons...